CJC-1295 with DAC (GHRH analogue): preparation and storage
Intended for research use only. Not a medicinal product.
Contents (11 sections)
DAC defines a different chemical form
CJC-1295 with a Drug Affinity Complex is a modified GHRH analogue carrying a reactive group for albumin attachment. Catalogues often use “CJC-1295 without DAC” for a different reagent, including modified GRF(1-29); molecular weight, pharmacokinetics and analytical conditions cannot be transferred between them. Check the presence, structure and condition of the DAC modification as well as the peptide component. A mass peak matching an unmodified chain does not establish an intact reactive group. Record that uncertainty before comparing results if the certificate lacks this information.
Batch identity and supplied form
Before opening, match the vial name, batch number, certificate of analysis and specification. Establish identity, stated mass, counterion, water, excipients and recommended conditions. “Lyophilized” describes a drying process; it does not establish purity, sterility or exact peptide content. HPLC main-peak area and peptide mass fraction are different measurements: water and salts may contribute little to that chromatogram. If the manufacturer has not established peptide content, label the concentration as calculated from nominal mass.
What the primary study measured
Teichman and colleagues conducted two randomized, placebo-controlled, double-blind studies in healthy adults, measuring CJC-1295 pharmacokinetics and GH and IGF-1 time profiles. Prolonged endocrine effects describe behavior in an organism with albumin, distribution and elimination. They do not directly measure free-peptide activity in protein-free buffer. A laboratory experiment reproducing one step must identify that step, such as albumin attachment or GHRH-receptor response. One endpoint cannot establish every property of a long-acting reagent.
Albumin participates in the experiment
For a DAC reagent, albumin may be a chemical binding partner rather than merely a carrier limiting adsorption. Adding BSA by habit changes the material under study. Define whether the assay concerns free reagent, conjugation kinetics or the attached product. Record albumin source and concentration, contact time, pH and temperature. Reductants and small thiols such as DTT or cysteine can compete with the intended reaction; do not introduce them without compatibility testing. Serum-containing medium and a defined protein-free buffer are not equivalent matrices.
Mass calculations and working dilutions
An arithmetic example, not a solubility prescription: 2 mg in a final volume of 4 mL gives 0.5 mg/mL, or 500 micrograms/mL. Adding 20 microliters of that stock to 980 microliters of compatible matrix gives 10 micrograms/mL. Then 100 microliters of this solution plus 900 microliters of matrix gives 1 microgram/mL. Use the final volume in the calculation. If the certificate separately establishes peptide mass fraction, apply it according to the labeling convention, without correcting the mass twice. Molarity requires the molecular weight of the confirmed form; do not borrow a value from a related analogue.
Chemical checks must distinguish forms
A falling free CJC-1295 DAC peak after albumin contact can indicate intended attachment rather than degradation. Conversely, retained total peptide mass does not establish retained conjugation capacity. Choose an analytical method that distinguishes free material, protein-bound product and unwanted changes to the reactive group. A separate GHRH-receptor assay can establish function of the peptide component but cannot alone establish DAC performance. Batch comparisons require consistent conjugation conditions and sample preparation.
Free fraction and total quantity require different samples
After DAC contacts protein, precipitation or ultrafiltration can separate fractions with different analyte contents. Measuring only the supernatant does not describe total material. Define the fraction the method should recover and include a sample-preparation recovery control. A protein conjugate may need a different identification method from the original small peptide. Clean-buffer calibration does not automatically compensate for losses during albumin sample handling. Report total concentration, measured free fraction and the procedure used to obtain each separately.
Long action does not establish storage lifetime
Teichman and colleagues studied prolonged endocrine effects of CJC-1295 in humans in 2006. Those data do not establish the stability of an opened vial in water and do not apply to a DAC-free form. Can stock be refrigerated for the reported biological half-life? That conclusion is unsupported. Can it be premixed with another secretagogue? The mixture needs separate chemical compatibility and analytical separation checks. Sealing and moisture protection are especially relevant to dry stocks; solutions require separate validation of DAC reactivity over the intended interval.
Water, reactive groups and dry stocks
Avoid opening a cold dry-CJC-1295-DAC vial in humid air: condensation creates a local aqueous phase before controlled dissolution. Use the specified freezer temperature and equilibrate the sealed vial before opening. Solutions require checks of both peptide integrity and reactive-group condition. An old solution retaining GHRH-receptor activity may be unsuitable for conjugation. Set separate acceptance criteria and controls for each purpose. Without storage data, prepare fresh working material within a validated procedure rather than assigning arbitrary refrigerator weeks.
End of article
CJC-1295 with DAC
for laboratory research
Packs and current prices on the product page.